# EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer

> **NCT02001272** · PHASE2 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 120 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Paclitaxel + Carboplatin every 3 weeks
- **DRUG:** Carboplatin monotherapy every 3 weeks
- **DRUG:** Weekly Paclitaxel and Carboplatin

## Key facts

- **NCT ID:** NCT02001272
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2020-02
- **Final completion:** 2020-02
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02001272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02001272, "EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02001272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*